Artiva Biotherapeutics, Inc.
ARTV
$5.52
-$0.28-4.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 3.51% | -1.29% | -4.64% | -26.19% | 7.88% |
| Total Depreciation and Amortization | 0.60% | 3.28% | 2.07% | 2.28% | -2.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.88% | 22.50% | -21.75% | 16.37% | -48.67% |
| Change in Net Operating Assets | 943.99% | 111.47% | -129.32% | -378.14% | -110.34% |
| Cash from Operations | 23.31% | 16.46% | -15.84% | -35.43% | -26.17% |
| Capital Expenditure | 29.83% | 43.13% | -106.46% | -698.44% | 33.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.47% | -23.89% | 111.57% | 1,262.08% | 99.31% |
| Cash from Investing | -1.46% | -22.93% | 111.83% | 1,132.19% | 99.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.25% | 3.03% | 0.00% | 0.00% | 13.16% |
| Issuance of Common Stock | -- | -- | -100.00% | 500.00% | -99.99% |
| Repurchase of Common Stock | 16.35% | -166.67% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | -100.00% | 770.00% | 99.23% |
| Cash from Financing | -227.03% | 48.61% | -130.13% | 896.67% | -100.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 140.30% | -53.13% | 79.93% | 38.44% | -172.32% |